E-cadherin and beta-catenin are down-regulated in prostatic bone metastases.
dc.contributor.author | Bryden, A A G | |
dc.contributor.author | Hoyland, Judith A | |
dc.contributor.author | Freemont, Anthony J | |
dc.contributor.author | Clarke, Noel W | |
dc.contributor.author | Schembri Wismayer, D | |
dc.contributor.author | George, Nicholas J | |
dc.date.accessioned | 2009-09-08T10:48:57Z | |
dc.date.available | 2009-09-08T10:48:57Z | |
dc.date.issued | 2002-03 | |
dc.identifier.citation | E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. 2002, 89 (4):400-3 BJU Int. | en |
dc.identifier.issn | 1464-4096 | |
dc.identifier.pmid | 11872032 | |
dc.identifier.uri | http://hdl.handle.net/10541/80248 | |
dc.description.abstract | OBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours. | |
dc.language.iso | en | en |
dc.subject | Bone Cancer | en |
dc.subject | Prostatic Cancer | en |
dc.subject.mesh | Bone Neoplasms | |
dc.subject.mesh | Cadherins | |
dc.subject.mesh | Cytoskeletal Proteins | |
dc.subject.mesh | Down-Regulation | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Prostatic Neoplasms | |
dc.subject.mesh | RNA, Messenger | |
dc.subject.mesh | Trans-Activators | |
dc.subject.mesh | beta Catenin | |
dc.title | E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. | en |
dc.type | Article | en |
dc.contributor.department | Christie and Hope Hospital, University of Manchester, UK. | en |
dc.identifier.journal | BJU International | en |
html.description.abstract | OBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours. |